The YT blood group antigen is located on human red blood cell (RBC) acetylcholinesterase. Wild-type acetylcholinesterase, YT1, has histidine at codon 322, whereas the genetic variant of acetylcholinesterase, YT2, has asparagine. This mutation is located within exon 2 of the ACHE gene, an exon that is present in all alternatively spliced forms of acetylcholinesterase. Therefore, acetylcholinesterase in brain and muscle has the same mutation as RBC acetylcholinesterase. We compared the electrophoretic and kinetic properties of RBC acetylcholinesterases having His 322 or Asn 322. We HE YT BLOOD GROUP antigen was found to be located on human erythrocyte acetylcholinesterase (EC Human acetylcholinesterase has a high degree of sequence homology with other cholinesterases: in particular with acetylcholinesterase from Torpedo californica, whose x-ray structure has been dete~mined.~ In T californica acetylcholinesterase the amino acid homologous to His 322 is Lys 315. Although Lys 315 is located on the enzyme surface far from the entrance to the active site gorge, it was relevant to examine what effect if any the His322Asn mutation might have on the overall structure and on kinetic properties of human acetylcholinesterase. For this purpose, we compared the properties of acetylcholinesterase that had histidine (YT* l/ 1) or asparagine at codon 322 (YT*2/2).
HE YT BLOOD GROUP antigen was found to be located on human erythrocyte acetylcholinesterase (EC Human acetylcholinesterase has a high degree of sequence homology with other cholinesterases: in particular with acetylcholinesterase from Torpedo californica, whose x-ray structure has been dete~mined.~ In T californica acetylcholinesterase the amino acid homologous to His 322 is Lys 315. Although Lys 315 is located on the enzyme surface far from the entrance to the active site gorge, it was relevant to examine what effect if any the His322Asn mutation might have on the overall structure and on kinetic properties of human acetylcholinesterase. For this purpose, we compared the properties of acetylcholinesterase that had histidine (YT* l/ 1) or asparagine at codon 322 (YT*2/2).
T MATERIALS AND METHODS
Forty milliliters of blood from one homozygous YT*1/1 and one homozygous YT*2/2 person was drawn into sodium citrate anticoagulant. YT genotypes were determined by the capillary indirect-antiglobulin method as well as by DNA sequencing.' Erythrocyte ghosts were prepared by hypotonic lysis followed by washing in hypotonic Ghost suspensions were stored at -70°C. Protein concentration was measured with the BCA Protein Assay Reagent (23225E; Pierce, Rockford, IL).
Isoelectric points were estimated on protease-released active forms of acetylcholinesterase. Soluble active forms of acetylcholinesterase were generated by limited proteolysis of the membranebound enzyme using N-tosyl-L-Phenylalanine chloromethyl ketonetreated trypsin or papain attached to beaded agarose (Sigma, St Louis, MO). Six hundred microliters of ghost suspension was incubated with 75 pL of insoluble proteases for 5 minutes to 6 hours at 4°C. The proteolytic action was stopped by centrifugation and separation of supematants. Isofocusing was performed on immobilized pH gradient gels (Phast IEF gels; Pharmacia, Uppsala, Sweden) in the pH range 4 to 6.5. One microliter of the various supernatants corresponding to different incubation times with the proteases was applied to IEF gels. pH gradient curves were constructed with the use of the Pharmacia p1 standard protein mixture. Acetylcholinesterase on gels was detected by staining for enzyme activity according found no differences in the isoelectric point, mobility on nondenaturing gel electrophoresis, affinity for acetylthiocholine, activity per milligram of RBC ghost protein, substrate inhibition constants, binding to the peripheral site ligand (propidium), and binding to active site ligands (tetrahydroaminoacridine and edrophonium). Thus, although the point mutation elicits antibody production in nonmatching blood transfusion recipients, it has no effect on the enzymatic properties of acetylcholinesterase. 0 1994 by The American Society of Hematology.
to the method of Karnovsky and Roots" using 1 mmollL acetylthiocholine iodide as substrate.
Nondenaturing gel electrophoresis of Triton X-100-solubilized acetylcholinesterase was performed according to Toutant" at pH 8.9 (200 mmoVL Tris-glycine buffer) and at pH 5.3 (100 mmollL sodium acetate).
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RESULTS AND DISCUSSION
Several active bands were generated by the action of proteases on ghost acetylcholinesterase, as a function of incubation time. However, no significant p1 differences were observed between the partially proteolyzed active forms of YT*I/l and YT:%2/2 acetylcholinesterases. p1 ranged from 4.10 to 4.40 and smears were always present from pH 4.8 to 5.10. The absence of a detectable pl difference can be attributed to the mixture of fragment lengths produced by proteolysis as well as to the heterogeneity of charge in the three carbohydrate chains attached to acetylcholinesterase. These mask the charge difference that must be present in a peptide containing asparagine in place of histidine. Nondenaturing gel electrophoresis patterns (Fig I ) showed a single band whose mobility was identical for both enzymes whatever the pH of the electrophoresis buffer (5.3 or 8.9). These results indicate that ionization of the presumed solvent-exposed His 322 (expected pKa = 6) does not have a significant effect on the electric charge of the enzyme. Because both enzymes have an apparently identical charge to mass ratio. this implies that the mutation of histidine 322 to asparagine does not induce electrophoretically detectable enzyme conformation changes. Thus. the YT blood group polymorphism does not explain the electrophoretic variant reported by Coates and Simpson. ' Kinetic analysis did not show any differences between YT*I/I and YT*2/2 enzymes. As shown in Table 1 , K,,, V,,,:,,, and K,, were similar, indicating that the mutation has MASSON ET AL no effect on the catalytic mechanism of acetylthiocholine hydrolysis. No decrease in specific activity was associated with the Asn 322 mutation, suggesting that the His322Asn variant does not correspond to previously reported hereditary deficiencies of erythrocyte acetylcholinesterase.'. 5 Inhibition of acetylthiocholine hydrolysis by propidium, an inhibitor that interacts with the peripheral site, was found to be of a linear mixed type for both enzymes. Competitive inhibition constants (K,) and noncompetitive inhibition constants (Ki') were slightly higher (Table I ) for red blood cell (RBC) acetylcholinesterase than the values for recombinant human acetylcholinesterase (Ki
The explanation for the higher values is that the assays for RBC acetylcholinesterase were performed in a buffer with a higher ionic strength. It is known that ligand binding at the peripheral site is very sensitive to changes in ionic strength. with slight increases causing a weakening in affinity."' Edrophonium and tacrine, two inhibitors that interact with amino acids inside the active site gorge." inhibited both YTI and YT2 enzymes to the same extent. Edrophonium at S pmol/ L inhibited YT*1/1 by 47% and YT*2/2 by 50%; tacrine at 0.125 pmol/L inhibited YT*I/I by 40%-and YT*2/2 by 41%. These results provide evidence that binding to the peripheral site and to the active site gorge was not affected by the His322Asn mutation.
In addition to the His322Asn mutation. the ACHE gene is polymorphic at codon S61 of exon S.' Our YT*I/I sample was homozygous for Arg S6 I. whereas our YT*2/2 sample was homozygous for Pro 561. This second polymorphic site is within a peptide that is removed before attachment of the glycolipid anchor to the carboxy terminus. The peptide containing this mutation has never been observed in the acetylcholinesterase protein and is only known to exist from mRNA and cDNA studies. The mutation at codon S61 of exon S is unrelated to YT genotype.' If processing of the precursor form of acetylcholinesterase to the glycolipid anchored form were strongly affected by the Pro56 I Arg mutation. then the amount of mature glycolipid-anchored acetylcholinesterase in the RBC membrane might have been different in our samples. This was not the case: both enzymes had the same activity per milligram of ghost protein for acetylthiocholine iodide (3.2 pmollminlmg). acetyl(P-methy1)thiocholine iodide (2.6 pmol/min/mg). propionylthiocholine iodide ( I .S pmol/min/mg). and propionyl(P-methy1)thiocholine iodide (1.3 pmol/min/mg). This suggests that the ProS61Arg mutation does not reduce the amount of RBC acetylcholinesterase. 
org From
The His322Asn mutation is present not only in RBC acetylcholinesterase but also in muscle and brain acetylcholinesterase, and acetylcholinesterase in all tissues in which it is expressed. The evidence for this is that there is only one gene for human ACHE,18 which means that the RBC enzyme is made from the same ACHE gene as acetylcholinesterase in muscle and brain. Secondly, the exon that encodes histidine 322 is present in all alternatively spliced forms of acetylch~linesterase.'~ This is the same exon that encodes the active site serine 203, a component of the catalytic Our results indicate that the naturally occurring point mutation His322Asn has no effect on the overall structure of human acetylcholinesterase, its catalytic properties, or its affinity for peripheral and active site ligands. We conclude that the cholinergic function of acetylcholinesterase in nervous tissues and the neuromuscular junction is unaltered by the YT blood group polymorphism.
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NOTE ADDED IN PROOF
An exit channel for product release has been mapped to a region that includes His 322 (Lys 315 in Torpedo acetylcholinesterase) and contains several additional positively charged amino acids." The fact that mutation to a neutral amino acid, Asn 322, has no effect on catalysis suggests that the exit channel functions equally well whether position 322 is positively charged or neutral.
